Evidence that EphA4 plays a significant role in amyotrophic lateral sclerosis or motor neuron disease (MND)12, where prolonged therapy would be required, prompted us to explore the development of a more long-lived agent which could be delivered as a weekly bolus injection. The gene discussed is EPHA4; the disease is mild neurocognitive disorder.